ERT Integrates Asthma Measurement Device

May 18, 2016

ERT announces it has successfully integrated the fractional exhaled Nitric Oxide (FeNO) measurement device by Aerocrine, a Circassia subsidiary, into it’s diagnostic platform for spirometry, ECG and home monitoring for centralized clinical trials.

ERT has integrated Circassia’s fractional exhaled Nitric Oxide (FeNO) measurement device into its MasterScope diagnostic platform, and is available for clinical trials. The device assists clinicians in evaluating and comparing allergic airway inflammations in patients with underlying asthma.

Read the full release here.

Related Content:

News